About Atopic Dermatitis
Atopic dermatitis (also known as AD) is the most common type of eczema. More than 40 million people in the US and Europe have atopic dermatitis — which often appears as a red, itchy rash normally on the cheeks, arms and legs. Atopic dermatitis typically begins in childhood, usually in the first six months of a baby’s life. Even though it’s a common form of eczema, it’s also severe and long-lasting. Often, atopic dermatitis disappears as a child grows older, though some children will have atopic dermatitis flares into adulthood. Many people with atopic dermatitis have very dry and infection-prone skin.
Aim of MC2-11
Tacrolimus formulated in a Vaseline-like ointment is currently the most potent non-steroidal topical therapy for atopic dermatitis. However, the current marketed formulations of tacrolimus (0.1% and 0.03%) are greasy ointments that many patients do not like to use, resulting in non-compliance and poor real-life efficacy. In addition, such therapies do not address the symptom of very dry and infection-prone skin.
Using PAD™ Technology we aim to make a PAD™ cream based tacrolimus drug for treatment of moderate to severe atopic dermatitis that not only is anti-inflammatory, but also addresses the very dry and infection-prone skin.
MC2-11 PAD™ Cream quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. A solution intended to significantly improve daily quality of life of patients and provide a unique value proposition to payers, physicians and patients.
In preparation for phase 2a dose-finding study.
MC2-11 PAD™ Cream
Active ingredient: Tacrolimus
Indication: Atopic Dermatitis